PDE4A and pulmonary fibrosis: Given that inflammation plays an essential role in the pathogenesis of both COPD and pulmonary fibrosis, and that the major therapeutic effects of both roflumilast and nerandomilast are achieved through the targeting of PDE4 isoforms in lung inflammatory cells, what exactly are the differences between these two drugs?